Laser and injection combo for wet age-related macular degeneration
Part of Eyes & vision clinical trials.
This study tests a combination of standard eye injections and laser treatment for wet age-related macular degeneration, a condition where abnormal blood vessels leak fluid and harm vision. It aims to see if this combined approach is safe and effective, potentially reducing the number of injections needed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 50 or older
- Diagnosis of wet age-related macular degeneration (abnormal blood vessels under the retina)
- The active abnormal blood vessel is not directly in the very center of the macula (the part of the eye responsible for sharp vision)
- No major heart attack, stroke, or heart-related hospitalization in the past 4 months
- Less than 50% of the area within 300 micrometers of the fovea is affected by the active lesion
- No other serious eye conditions (like advanced cataracts or diabetic eye disease) that could affect vision outcomes
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a one-time gene therapy injection (4D-150) for wet AMD. It might help reduce the need for frequent anti-VEGF eye injections by targeting the underlying cause of new blood vessel growth.
This trial tests a new CRISPR-based treatment for wet age-related macular degeneration (AMD). It aims to stop vision loss by targeting the cause of abnormal blood vessel growth in the eye. This study is for people who have already tried anti-VEGF injections but might not be responding well enough.
This trial tests a new investigational injection, QL1207H, against an already approved drug (aflibercept) for people with wet age-related macular degeneration, a condition that causes rapid central vision loss. The goal is to see if the new injection works as well or better at stopping further vision loss and possibly improving sight.
This trial tests a new CRISPR-based gene therapy injected into the eye to treat wet age-related macular degeneration (AMD). It aims to stop the growth of abnormal blood vessels that damage your vision.
This study tests a one-time gene therapy called LX102 for wet age-related macular degeneration (AMD). It may reduce the need for frequent eye injections and help preserve vision.
This Phase 1 trial tests whether BBC1501, an injection given into the eye, is safe for people with wet age-related macular degeneration (nAMD). It mainly looks at side effects and whether the study injections can be given safely in patients who still have active disease despite prior anti-VEGF treatments.
Hear when a new Neovascular Age-Related Macular Degeneration (nAMD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.